Id |
Subject |
Object |
Predicate |
Lexical cue |
T130 |
0-8 |
Sentence |
denotes |
Table 2. |
T131 |
9-55 |
Sentence |
denotes |
Sensitivity and specificity of all test assays |
T132 |
56-149 |
Sentence |
denotes |
Test Assay Sensitivity day 2–7 Sensitivity day 8–18 Overall sensitivity day 2-d18 Specificity |
T133 |
150-220 |
Sentence |
denotes |
IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG IgM* + IgG IgM* IgG |
T134 |
221-261 |
Sentence |
denotes |
Point-of-care test |
T135 |
262-376 |
Sentence |
denotes |
Corona Virus (COVID-19) Combined IgM/IgG Rapid test (Sol scientifics) 57% 14% 57% 94% 88% 94% 83% 65% 83% 79% 100% |
T136 |
377-473 |
Sentence |
denotes |
COVID-19 IgG/IgM Rapid test Cassette (Orient Gene) 43% 29% 43% 94% 88% 94% 78% 70% 78% 100% 100% |
T137 |
474-517 |
Sentence |
denotes |
SARS-CoV-2 Ab rapid test (Wantai) n.a. n.a. |
T138 |
518-531 |
Sentence |
denotes |
43% n.a. n.a. |
T139 |
532-545 |
Sentence |
denotes |
94% n.a. n.a. |
T140 |
546-554 |
Sentence |
denotes |
78% n.a. |
T141 |
555-559 |
Sentence |
denotes |
100% |
T142 |
560-652 |
Sentence |
denotes |
COVID-19 IgG/IgM RAPID TEST (PRIMA PROFESSIONAL) 0% 29% 29% 50% 81% 88% 35% 65% 70% 95% 100% |
T143 |
653-761 |
Sentence |
denotes |
Diagnostic Kit for IgG/IgM Antibody to SARS-CoV-2 (WIZ BIOTECH) 14% 14% 14% 94% 94% 94% 70% 70% 70% 95% 100% |
T144 |
762-825 |
Sentence |
denotes |
Enzyme-Linked Immunosorbent Assay (ELISA) |
T145 |
826-899 |
Sentence |
denotes |
Anti-SARS-CoV-2 (EUROIMMUN)* 57% 29% 57% 94% 88% 94% 83% 70% 83% 95% 100% |
T146 |
900-992 |
Sentence |
denotes |
Novel Coronavirus COVID-19 (Epitope Diagnostics) 29% 71% 71% 69% 94% 94% 57% 87% 87% 95% 89% |
T147 |
993-1086 |
Sentence |
denotes |
SARS-CoV-2 IgG ELISA Kit (Creative Diagnostics) 29% 14% 29% 94% 88% 94% 74% 65% 74% 100% 100% |
T148 |
1087-1140 |
Sentence |
denotes |
Human Anti-2019 nCoV(N) IgG ELISA kit (Finetest) n.a. |
T149 |
1141-1154 |
Sentence |
denotes |
29% n.a. n.a. |
T150 |
1155-1168 |
Sentence |
denotes |
88% n.a. n.a. |
T151 |
1169-1182 |
Sentence |
denotes |
70% n.a. n.a. |
T152 |
1183-1186 |
Sentence |
denotes |
83% |
T153 |
1187-1256 |
Sentence |
denotes |
Chemiluminescent microparticle immunoassay (CMIA) |
T154 |
1257-1285 |
Sentence |
denotes |
SARS-CoV-2 IgG (Abbott) n.a. |
T155 |
1286-1299 |
Sentence |
denotes |
29% n.a. n.a. |
T156 |
1300-1313 |
Sentence |
denotes |
88% n.a. n.a. |
T157 |
1314-1327 |
Sentence |
denotes |
70% n.a. n.a. |
T158 |
1328-1332 |
Sentence |
denotes |
100% |
T159 |
1333-1391 |
Sentence |
denotes |
Chemiluminescence immunoassay (CLIA) |
T160 |
1392-1436 |
Sentence |
denotes |
Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) n.a. |
T161 |
1437-1449 |
Sentence |
denotes |
0% n.a. n.a. |
T162 |
1450-1463 |
Sentence |
denotes |
81% n.a. n.a. |
T163 |
1464-1477 |
Sentence |
denotes |
59% n.a. n.a. |
T164 |
1478-1482 |
Sentence |
denotes |
100% |
T165 |
1483-1512 |
Sentence |
denotes |
Anti-SARS-CoV-2 (EUROIMMUN)*: |
T166 |
1513-1553 |
Sentence |
denotes |
IgA instead of IgM; n.a.: not applicable |